AbbVie Inc. (ABBV): Price and Financial Metrics

AbbVie Inc. (ABBV)

Today's Latest Price: $92.92 USD

0.35 (0.38%)

Updated Aug 7 12:00am

Add ABBV to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ABBV Stock Summary

  • With a market capitalization of $163,988,305,218, AbbVie Inc has a greater market value than 99.08% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -42.76 for AbbVie Inc; that's greater than it is for just 0.61% of US stocks.
  • In terms of volatility of its share price, ABBV is more volatile than just 4.46% of stocks we're observing.
  • Stocks that are quantitatively similar to ABBV, based on their financial statements, market capitalization, and price volatility, are AMGN, ASX, GLW, TXN, and ITRI.
  • Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to
ABBV Daily Price Range
ABBV 52-Week Price Range

ABBV Stock Price Chart Technical Analysis Charts

ABBV Price/Volume Stats

Current price $92.92 52-week high $101.28
Prev. close $92.57 52-week low $62.55
Day low $92.20 Volume 5,227,000
Day high $93.00 Avg. volume 10,561,658
50-day MA $96.18 Dividend yield 5.08%
200-day MA $87.89 Market Cap 163.99B

AbbVie Inc. (ABBV) Company Bio

Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$92.92$242.43 160%

We started the process of determining a valid price forecast for AbbVie Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that AbbVie Inc ranked in the 67th percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 161.33%. The most interesting components of our discounted cash flow analysis for AbbVie Inc ended up being:

  • The company's balance sheet shows it gets 64% of its capital from equity, and 36% of its capital from debt. Notably, its equity weight is greater than only 18.86% of US equities in the Healthcare sector yielding a positive free cash flow.
  • AbbVie Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than only 7.31% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

NVO, DVA, PCRX, LXRX, and EGRX can be thought of as valuation peers to ABBV, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

ABBV Latest News Stream

Event/Time News Detail
Loading, please wait...

ABBV Latest Social Stream

Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

3 Low-Beta Blue Chips With High Dividend Yields

When it comes to evaluating returns on investment, the term “alpha” gets used a lot. For those unaware of what this term means, alpha refers to the percentage of return on investment above the risk-free rate, of which the Treasury bond rate is commonly used as a proxy. Stocks and...

Gen Alpha on Seeking Alpha | July 30, 2020

Riverdale's Madelaine Petsch speaks against birth control taboo

EXCLUSIVE: The 25-year-old actress fronts a new campaign for AbbVie birth control pill Lo Loestrin Fe, which aims to educate women about their choices.

Daily Mail Online | July 30, 2020

A Preview Of AbbVie's Earnings

On Friday, July 31, AbbVie (NYSE: ABBV) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.Earnings and Revenue Analysts covering AbbVie modeled for quarterly EPS of $2.19 on revenue of $10.08 billion. AbbVie reported a per-share profit of $2.260 when it published results during the same quarter last year. Sales in that period totaled $8.26 billion. If the company were to match the consensus estimate, earnings would be down 3.1%. Revenue would be up 21.01% from the same quarter last year. AbbVie's reported EPS has stacked up against analyst estimates in the past like this:Quarter Q1 2020 Q4 2020 Q3 2019 Q2 2019 EPS Estimate 2.25 2.19 2.30 2.20 EPS Actual 2.42 2.21 2.33 2.26 Revenue Estimate 8.33 B 8.70 B...

Yahoo | July 30, 2020

Why Earnings Season Could Be Great for AbbVie (ABBV)

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | July 30, 2020

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Yahoo | July 29, 2020

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo -2.87%
3-mo 7.00%
6-mo -0.57%
1-year 49.68%
3-year 51.82%
5-year 69.06%
YTD 9.27%
2019 1.47%
2018 -0.96%
2017 60.07%
2016 9.79%
2015 -6.50%

ABBV Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9478 seconds.